Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Management of hypertriglyceridemia in the diabetic patient.

Jialal I, Amess W, Kaur M.

Curr Diab Rep. 2010 Aug;10(4):316-20. doi: 10.1007/s11892-010-0124-4. Review.

2.

Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Ito MK.

Atherosclerosis. 2015 Oct;242(2):647-56. doi: 10.1016/j.atherosclerosis.2015.06.012. Epub 2015 Jun 11. Review.

PMID:
26296750
3.

Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol.

Toth PP, Zarotsky V, Sullivan JM, Laitinen D.

Curr Med Res Opin. 2009 Jun;25(6):1355-63. doi: 10.1185/03007990902910450.

PMID:
19425901
4.

[Lipid therapy in patients with diabetes].

Saely CH, Drexel H.

Wien Med Wochenschr. 2010 Jan;160(1-2):25-9. doi: 10.1007/s10354-010-0745-x. Review. German.

PMID:
20229158
5.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
6.

TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.

Handelsman Y, Shapiro MD.

Endocr Pract. 2017 Jan;23(1):100-112. doi: 10.4158/EP161445.RA. Epub 2016 Nov 7. Review.

PMID:
27819772
7.

Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.

Nichols GA, Reynolds K, Olufade T, Kimes TM, O'Keeffe-Rosetti M, Sapp DS, Anzalone D, Fortmann SP.

Am J Cardiol. 2017 Feb 1;119(3):410-415. doi: 10.1016/j.amjcard.2016.10.029. Epub 2016 Nov 4.

PMID:
27890243
8.

Hypertriglyceridemia: the importance of identifying patients at risk.

Kushner PA, Cobble ME.

Postgrad Med. 2016 Nov;128(8):848-858. Epub 2016 Oct 12. Review.

PMID:
27710158
9.
10.

Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.

Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):427-32. doi: 10.1161/ATVBAHA.113.302019. Epub 2013 Nov 27.

11.

Triglyceride as a risk factor for coronary artery disease.

Gotto AM Jr.

Am J Cardiol. 1998 Nov 5;82(9A):22Q-25Q. Review.

PMID:
9819100
12.
13.

Treating hypertriglyceridemia.

Holub BJ.

CMAJ. 2007 Sep 11;177(6):604; author reply 604-5. No abstract available.

14.

Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.

Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.

J Cardiovasc Pharmacol. 2008 Apr;51(4):331-51. doi: 10.1097/FJC.0b013e318165e2e7. Review.

PMID:
18427276
15.

Demystifying triglycerides: a practical approach for the clinician.

Dunbar RL, Rader DJ.

Cleve Clin J Med. 2005 Aug;72(8):661-6, 670-2, 674-5 passim. Review.

PMID:
16122052
16.

'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.

Jacobson TA.

Int J Clin Pract. 2011 Jan;65(1):82-101. doi: 10.1111/j.1742-1241.2010.02547.x. Epub 2010 Nov 24. Review.

PMID:
21105969
17.

Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.

Vega GL, Grundy SM.

Am J Cardiol. 1998 Feb 26;81(4A):36B-42B. Review.

PMID:
9526812
18.

Managing diabetic dyslipidemia: beyond statin therapy.

Neeli H, Gadi R, Rader DJ.

Curr Diab Rep. 2009 Feb;9(1):11-7. Review.

PMID:
19192419
19.

Dyslipidemia and cardiovascular risk: the importance of early prevention.

Miller M.

QJM. 2009 Sep;102(9):657-67. doi: 10.1093/qjmed/hcp065. Epub 2009 Jun 4.

20.

[Diabetic dyslipoproteinemia].

Geiss HC, Parhofer K.

MMW Fortschr Med. 2006 Apr 6;148(14):30-3. German.

PMID:
16669277

Supplemental Content

Support Center